Impact of Sequence Variation in the UL128 Locus on Production of Human Cytomegalovirus in Fibroblast and Epithelial Cells

Isa Murrell, Peter Tomasec, Gavin S. Wilkie, Derrick J. Dargan, Andrew J. Davison and Richard J. Stanton

*J. Virol.* 2013, 87(19):10489. DOI: 10.1128/JVI.01546-13. Published Ahead of Print 24 July 2013.

Updated information and services can be found at:
http://jvi.asm.org/content/87/19/10489

These include:

**REFERENCES**

This article cites 81 articles, 51 of which can be accessed free at: http://jvi.asm.org/content/87/19/10489#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more

Information about commercial reprint orders: http://journals.asm.org/site/misc/reprints.xhtml
To subscribe to another ASM Journal go to: http://journals.asm.org/site/subscriptions/
Impact of Sequence Variation in the UL128 Locus on Production of Human Cytomegalovirus in Fibroblast and Epithelial Cells

Isa Murrell, a Peter Tomasec, a Gavin S. Wilkie, a Derrick J. Dargan, b Andrew J. Davison, b Richard J. Stanton a

Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom; MRC–University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

The human cytomegalovirus (HCMV) virion envelope contains a complex consisting of glycoproteins gH and gL plus proteins encoded by the UL128 locus (UL128L): pUL128, pUL130, and pUL131A. UL128L is necessary for efficient infection of myeloid, epithelial, and endothelial cells but limits replication in fibroblasts. Consequently, disrupting mutations in UL128L are rapidly selected when clinical isolates are cultured in fibroblasts. In contrast, bacterial artificial chromosome (BAC)-cloned strains TB40-BAC4, FIX, and TR do not contain overt disruptions in UL128L, yet no virus reconstituted from them has been reported to acquire mutations in UL128L in vitro. We performed BAC mutagenesis and reconstitution experiments to test the hypothesis that these strains contain subtle mutations in UL128L that were acquired during passage prior to BAC cloning. Compared to strain Merlin containing wild-type UL128L, all three strains produced higher yields of cell-free virus. Moreover, TB40-BAC4 and FIX spread cell to cell more rapidly than wild-type Merlin in fibroblasts but more slowly in epithelial cells. The differential growth properties of TB40-BAC4 and FIX (but not TR) were mapped to single-nucleotide substitutions in UL128L. The substitution in TB40-BAC4 reduced the splicing efficiency of UL128, and that in FIX resulted in an amino acid substitution in UL130. Introduction of these substitutions into Merlin dramatically increased yields of cell-free virus and increased cell-to-cell spread in fibroblasts but reduced the abundance of pUL128 in the virion and the efficiency of epithelial cell infection. These substitutions appear to represent mutations in UL128L that permit virus to be propagated in fibroblasts while retaining epithelial cell tropism.

H uman cytomegalovirus (HCMV) is ubiquitous throughout populations worldwide and represents a significant public health challenge in both developed and developing countries (1). Like other herpesviruses, HCMV establishes life-long persistent infections with periodic episodes of reactivation that require constant immunosurveillance. Productive infection is commonly asymptomatic in an immunocompetent host, but the virus remains a leading infectious cause of congenital malformation and is responsible for a broad spectrum of pathological consequences in immunocompromised (e.g., AIDS patients) or immunosuppressed individuals (e.g., transplant recipients). HCMV displays tropism for a broad range of cell types and tissues in vivo, with disease being associated with most major organs. For example, initial infection occurs in mucosal epithelial tissues, infection of endothelial tissues can result in transfer of virus to solid organs and leukocytes for dissemination, and CD34+ bone marrow progenitor cells and monocytes are sites of latency (1–3). Thus, studies of HCMV pathogenesis require the use of virus with the ability to infect a wide range of cell types in vitro. However, there are significant challenges associated with in vitro propagation of virus that exhibits the broad tropism characteristic of clinical virus.

Classically, three distinct virion envelope glycoprotein complexes, designated gC1, gCII, and gCIII, have been implicated in recognition and uptake of HCMV by the cell. gC1, composed of glycoprotein gB, and gCII, composed of glycoproteins gM and gN, mediate the initial attachment of virions. Both are capable of binding to heparin sulfate proteoglycans (4–7), while gB is also capable of binding to integrins, epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor α (PDGFRα). All of these molecules have been reported to be important for virus entry (8–11), although the roles of EGFR and PDGFRα have been disputed (12, 13). Following initial binding, fusion with cellular membranes is orchestrated by gB and gCIII, which is formed of glycoproteins gH, gL, and gO (14–18). More recently it has become apparent that gH and gL also form a second glycoprotein complex, and that infection of different cell types occurs by different mechanisms involving these two different complexes.

Infection of fibroblasts occurs by direct fusion of the virion envelope with the plasma membrane, whereas in epithelial, endothelial, and myeloid cells, membrane fusion takes place in vesicles following internalization by endocytosis or micropinocytosis (19–22). gH/gL/gO is required for infection, viroparticle formation, egress, and cell-to-cell spread in fibroblasts, as well as for infection of epithelial and endothelial cells (6, 23, 24). A second complex, gH/gL/UL128L, is formed by gH/gL along with the products of the UL128 locus (UL128L), pUL128, pUL130, and pUL131A. gH/gL, UL128L is required for efficient infection and cell-to-cell spread in epithelial, endothelial, and myeloid cells (22, 25–35), either by binding to cell surface receptors (22, 27, 28) or by promoting nuclear translocation of virions (21, 32, 36). Infection of fibroblasts does not require gH/gL/UL128L; in fact, virus containing gH/gL/UL128L displays reduced cell-to-cell spread and cell-free release in fibroblasts in vitro (37, 38). As a result, there is considerable selection pressure against UL128L in this cell type. Thus, routine isolation of HCMV strains from clinical material in fibroblasts is associated with rapid acquisition of disabling mutations in UL128L, which are usually apparent as frameshifts caused by
insertion or deletion of one or more nucleotides, in-frame termination codons caused by single-nucleotide substitutions, or deletions (37–44). This results in the generation of laboratory-adapted viruses that display efficient growth in fibroblasts but limited growth in other cell types.

To provide a genetically stable source of HCMV, the genome can be cloned into a bacterial artificial chromosome (BAC) and virus recovered by transfection (38, 45–47). However, HCMV is invariably subjected to some degree of passaging in vitro prior to BAC cloning, and as a result, BAC-cloned strains exhibit various degrees of in vitro adaptation. We have previously described the cloning of the complete HCMV strain Merlin genome into a self-excising BAC following five passages in fibroblasts (38). In vitro-acquired mutations were identified by reference to the original clinical material and repaired, with the resulting BAC having the genetic competence of wild-type virus. However, as with clinical HCMV strains, the presence of wild-type UL128L in reconstituted virus results in the production of very low titers of cell-free virus in vitro, and the virus is prone to mutation when passed in fibroblasts (38).

Several HCMV strains in addition to Merlin have been BAC cloned. These include TB40-BAC4, which was cloned from a mixed population of TB40/E following five passages in fibroblasts and 22 passages in endothelial cells (48), FIX, which was derived from strain VR1814 following 46 passages in fibroblasts (49, 50), and TR, which was isolated from an ocular swab from an AIDS patient (51, 52). Strains TB40-BAC4, FIX, and TR were cloned by replacing sequences in one region of the genome (at the left end of U4) with a nonexcising BAC vector. UL128L in each BAC is apparently intact, and reconstituted virus is able to infect epithelial and endothelial cells. However, unlike strains isolated from clinical material, there are no reports of viruses reconstituted from these BACs acquiring mutations in UL128L during passage in vitro. This raised the hypothesis that these viruses contain subtle mutations in UL128L that were acquired during passage of the clinical isolates prior to BAC cloning. Indeed, our study identifies single-nucleotide substitutions in strains TB40-BAC4 and FIX that impact UL128 and UL130, respectively. Introduction of these substitutions into wild-type UL128L in strain Merlin dramatically increased yields of cell-free virus and increased cell-cell spread in fibroblasts but reduced both the abundance of pUL128 in the virion and the efficiency of infection in epithelial cells.

MATERIALS AND METHODS

Cells and viruses. Primary human fetal foreskin fibroblast (HFF) cells and human telomerase reverse transcriptase (hTERT)-immortalized retinal pigmented epithelial (RPE-1) cells were grown in Dulbecco’s modified Eagle medium (DMEM) (Life Technologies) supplemented with fetal bovine serum (10%, vol/vol), penicillin (500 U/ml), and streptomycin (500 μg/ml) at 37°C in 5% CO2. Two variants of the Merlin BAC were used and have been described previously (38). Merlin-UL128Lmut (previously called pAL1158) contains a premature stop codon in UL128, while Merlin-UL128Lwt (previously called pAL1160) contains wild-type UL128. Both BACs contain a frameshift in RL13 and an internal ribosomal entry site (IRES) followed by enhanced green fluorescent protein (EGFP) after UL122. TB40-BAC4 was kindly donated by Christian Sinzger (48), FIX by Gabi Hahn (50), and TR by Jay Nelson (51). For these BACs, recombinering was used to insert an IRES followed by EGFP after UL122 as described previously (38). HCMV strain 3301 DNA had been extracted previously from the urine of a congenitally infected infant (40).

Infections were performed at 37°C for 2 h on a rocker, followed by removal of the inoculum and addition of fresh medium (53). In titrations and assays to investigate cell-to-cell spread, supernatant-driven spread was limited by use of a 1% Avicel semisolid overlay (54). After incubation for 14 days (for fibroblasts) or 21 days (for epithelial cells), the overlay was removed and cells were washed in phosphate-buffered saline (PBS). Unless otherwise stated, quantitation of cell-free virus produced during infection of both fibroblast and epithelial cells was performed using HFFF, since this is the only cell type in which all viruses could infect and spread. Plaques were identified based on EGFP expression and imaged using an ORCA-ER camera and Leica DMRBRE microscope. Plaque sizes were determined using OpenLab 3 software.

Preparation of BACs. Stocks of each BAC-cloned genome were prepared using a Nucleobond plasmid purification kit (Macherey-Nagel) according to the manufacturer’s instructions. The concentration of purified plasmid DNA was determined by use of an ND1000 spectrophotometer (NanoDrop).

Transformations. BACs were transfected into HFFF cells by electroporation using a Nucleofector (Amaxa) and basic fibroblast kit (Lonza) and program T-16 according to the manufacturer’s instructions. On occasions when the monolayer formed was less than 70% confluent on the following day, additional cells were added. The number of plaques formed following electroporation varied only marginally, ranging from 20 to 35 per transfection. RPE-1 cells were transfected using Effectene (Qiagen) according to the manufacturer’s instructions. The number of plaques formed varied only minimally, with 50 to 70 plaques generated per transfection. These variations were not observed to have a major impact on the relative rate of virus spread through the monolayer in experimental repeats.

FACS analysis. At weekly time points posttransfection, infected RPE-1 cultures were trypsinized and resuspended into fresh flasks. An aliquot of cells was kept for fluorescence-activated cell sorter (FACS) analysis using an Accuri C6 and CFlow software for the detection of EGFP+ cells.

Recombinering. All recombinering was performed as described previously (38, 55, 56), using E. coli SW102 cells containing the BAC to be modified. A selectable ampicillin cassette was PCR amplified and inserted into the region to be modified, followed by positive selection for expression of ampicillin resistance on medium supplemented with ampicillin (50 μg/ml). In a second round of recombinering, the selection cassette was swapped with the DNA sequence to be inserted, followed by negative selection on medium supplemented with sucrose (5%, wt/vol) to select against sacB expression and 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) and isopropyl-β-d-thiogalactoside (IPTG) to identify white colonies lacking lacZ expression. Amplification of the selectable cassette was performed using the Expand HiFi system (Roche) under the following conditions: 95°C for 2 min; 10 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 4.5 min; 25 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 4.5 min; and 68°C for 15 min. Primer pairs were designed with approximately 20 bp of identity to the selectable cassette at each 3’ end and approximately 80 bp of identity to sequences adjacent to the insertion site at the 5’ end. In the primer sequences shown below, regions identical to sequences immediately upstream and downstream from the insertion site are underlined. Primers were designed to cover regions with 100% identity in all strains.

Insertion of UL128L sequences into the Merlin genome. For insertion of the complete UL128L from strains TB40-BAC4, FIX, and 3301 in place of the wild-type Merlin UL128L, the ampicillin cassette was PCR amplified using primers SacBR-131A (CAG TCT GCA ACA TGC GGC TGT GTC GGG TGT GGC TGT CTG TTT GTC TGT GCG CCG TGG TGC TGG TGC ATG GCC AGC GGC GAG ACT GAG CTTG CTG TTT GGG CAG CCT GGT CCT G) and SacBF-128 (ATC CAG CCG TTT GTG TTT CTG AAG CCG TGC GTC CAG GTA CTG ATC GAG CCG CAC GAT CCG GTG TAT CTT GTC GTA TTC CAG CCT GTG ACG GAA GAT CAC TCC G). On occasion, the monolayer formed was less than 70% confluent on the following day, additional cells were added. The number of plaques formed following electroporation varied only marginally, ranging from 20 to 35 per transfection. These variations were not observed to have a major impact on the relative rate of virus spread through the monolayer in experimental repeats.

FACS analysis. At weekly time points posttransfection, infected RPE-1 cultures were trypsinized and resuspended into fresh flasks. An aliquot of cells was kept for fluorescence-activated cell sorter (FACS) analysis using an Accuri C6 and CFlow software for the detection of EGFP+ cells.

Recombinering. All recombinering was performed as described previously (38, 55, 56), using E. coli SW102 cells containing the BAC to be modified. A selectable ampicillin cassette was PCR amplified and inserted into the region to be modified, followed by positive selection for expression of ampicillin resistance on medium supplemented with ampicillin (50 μg/ml). In a second round of recombinering, the selection cassette was swapped with the DNA sequence to be inserted, followed by negative selection on medium supplemented with sucrose (5%, wt/vol) to select against sacB expression and 5-bromo-4-chloro-3-indolyl-β-d-galactopyranoside (X-Gal) and isopropyl-β-d-thiogalactoside (IPTG) to identify white colonies lacking lacZ expression. Amplification of the selectable cassette was performed using the Expand HiFi system (Roche) under the following conditions: 95°C for 2 min; 10 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 4.5 min; 25 cycles at 95°C for 30 s, 55°C for 30 s, and 68°C for 4.5 min; and 68°C for 15 min. Primer pairs were designed with approximately 20 bp of identity to the selectable cassette at each 3’ end and approximately 80 bp of identity to sequences adjacent to the insertion site at the 5’ end. In the primer sequences shown below, regions identical to sequences immediately upstream and downstream from the insertion site are underlined. Primers were designed to cover regions with 100% identity in all strains.

Insertion of UL128L sequences into the Merlin genome. For insertion of the complete UL128L from strains TB40-BAC4, FIX, and 3301 in place of the wild-type Merlin UL128L, the ampicillin cassette was PCR amplified using primers SacBR-131A (CAG TCT GCA ACA TGC GGC TGT GTC GGG TGT GGC TGT CTG TTT GTC TGT GCG CCG TGG TGC TGG TGC ATG GCC AGC GGC GAG ACT GAG CTTG CTG TTT GGG CAG CCT GGT CCT G) and SacBF-128 (ATC CAG CCG TTT GTG TTT CTG AAG CCG TGC CAG GTA CTG ATC GAG CCG CAC GAT CCG GTG TAT CTT GTC GTA TTC CAG CCT GTG ACG GAA GAT CAC TCC G). On occasion, the monolayer formed was less than 70% confluent on the following day, additional cells were added. The number of plaques formed following electroporation varied only marginally, ranging from 20 to 35 per transfection. These variations were not observed to have a major impact on the relative rate of virus spread through the monolayer in experimental repeats.
was performed under the following conditions: 98°C for 1 min; 35 cycles at 98°C for 30 s, 55°C for 30 s, and 72°C for 1 min; and 72°C for 10 min.

**Insertion of the unique TB40-BAC4 nucleotide into the Merlin genome.** The *amp/sacB/lacZ* selection cassette was amplified using primers SacBF (GGT GGT GAC GAT CCC GGC AAT CTC AGC GGT TTG TTC GGC AGT GAC TTA GCA GCA TTC GGC AAC CGG CAC CCT GTG GCT TGG GAT ACC TGG AAC CCC GAT AAT TTG ATT CAT GAA AAT CTA CTC TGG CAT TCC CGA GGA TCG CAG TAA A). The following oligonucleotide was used to insert the TB40-BAC4 UL128 nucleotide (underlined): GAG GTC TCG TTG CGA GGA CTG TAG CAG ACT TCG CCG TCC GGA CAC CGC AGT TTG ATT CAT GAA AAT CTA CTC TGG CAT TCC CGA GGA TCG TGG ATG GAA CAT G.

**Insertion of unique FIX UL130 nucleotide into the Merlin genome.** The *amp/sacB/lacZ* selection cassette was amplified using primers SacBF-FIX (GTC TGC CCT TCC CGG TTG TAC AGC AGA TAC AGC TTC GGG ACG GCC GAA GAT CAC TTC GAC CGT TTT CTC AAT GCC AGA GTA GAT TTT CAT GAA TCT GAG CTG TCT CTC GAC GTT TCT GAT AGC CAT GTT CCA TCG ACG TGC TAA AAT GCG TAT CAG ACT TCG TGG CGC TCG GGA CCC GTT CAT TCC CGA GGA TAG CTT AGT GAA CAT G.

**Sanger DNA sequencing.** UL128L was amplified by PCR using primers UL128LF (GCG TAT TTC GCG GCA CCC GTC GGA CAC CGC GAA GAT CCC GTG ACG GAA GAT CAC TTC G) and SacBR-FIX (TAT TCC AAA CCA GCG GAC GGG GAC TTT TAC TAC CTT CTC TTC CTG CCG CCC CCA GGA TCC CCC TGG CAA TCC GTG CAG GTT CCT ATG GC TGT C). The following oligonucleotide was used to insert the FIX UL130 nucleotide (underlined): AGG GTC TGG CCT TCC CGG TTG TAC AGC AGA TAC AGC TTC GGG AAT GCC AGA GTA GAT TTT CAT GAA TCT GAG CTG TCT CTC GAC GTT TCT GAT AGC CAT GTT CCA TCG ACG TGC TAA AAT GCG TAT CAG ACT TCG TGG CGC TCG GGA CCC GTT CAT TCC CGA GGA TAG CTT AGT GAA CAT G.

**Gradient purification of virions.** Virions were purified from noninfectious enveloped particles, dense bodies, and cellular debris by ultracentrifugation through glycerol-tartrate positive-density, negative-viscosity gradients, as described previously (62, 63). The gradients were centrifuged at 90,465.7 × g for 45 min at 20°C. Virions were recovered by piercing the tubes using a 20-gauge needle and syringe, diluted in 0.04 M sodium phosphate buffer (pH 7.4), and pelleted by centrifugation at 90,465.7 × g for 1 h at 20°C. The virion pellet was resuspended in a medium suitable for downstream applications (see below).

**Western blot analysis.** Purified virions were resuspended in Nu-Page LDS sample buffer, and proteins were separated by using a Nu-page Tris-acetate gel system (Invitrogen) according to the manufacturer’s instructions. Electrophoresed proteins were subsequently transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare) by semidy transfer at 10 V for 1 h using carbonate transfer buffer. The membranes were incubated for 1 h at room temperature in blocking buffer (PBS containing 0.1% Tween 20 [PBST] plus 5% [wt/vol] fat-free milk). They were then incubated with primary antibody for 1 h at room temperature, washed three times with PBST, and incubated with secondary antibody for 1 h at room temperature. Antibody was detected by SuperSignal West Pico (Thermo) using an AutoChem imaging system and Labworks software (UVP Bioimaging). Primary antibodies were mouse-anti pUL128 antibody SURN, provided by Giueseppe Gerna (1:100), and mouse anti-gB (1:4,000; Abcam). The secondary antibody was goat anti-mouse horseradish peroxidase (HRP; 1:1,000; GE Healthcare).

**RESULTS**

**Gradient purification of virions.** Virions were purified from noninfectious enveloped particles, dense bodies, and cellular debris by ultracentrifugation through glycerol-tartrate positive-density, negative-viscosity gradients, as described previously (62, 63). The gradients were centrifuged at 90,465.7 × g for 45 min at 20°C. Virions were recovered by piercing the tubes using a 20-gauge needle and syringe, diluted in 0.04 M sodium phosphate buffer (pH 7.4), and pelleted by centrifugation at 90,465.7 × g for 1 h at 20°C. The virion pellet was resuspended in a medium suitable for downstream applications (see below).

**Western blot analysis.** Purified virions were resuspended in Nu-Page LDS sample buffer, and proteins were separated by using a Nu-page Tris-acetate gel system (Invitrogen) according to the manufacturer’s instructions. Electrophoresed proteins were subsequently transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare) by semidy transfer at 10 V for 1 h using carbonate transfer buffer. The membranes were incubated for 1 h at room temperature in blocking buffer (PBS containing 0.1% Tween 20 [PBST] plus 5% [wt/vol] fat-free milk). They were then incubated with primary antibody for 1 h at room temperature, washed three times with PBST, and incubated with secondary antibody for 1 h at room temperature. Antibody was detected by SuperSignal West Pico (Thermo) using an AutoChem imaging system and Labworks software (UVP Bioimaging). Primary antibodies were mouse-anti pUL128 antibody SURN, provided by Giueseppe Gerna (1:100), and mouse anti-gB (1:4,000; Abcam). The secondary antibody was goat anti-mouse horseradish peroxidase (HRP; 1:1,000; GE Healthcare).

**RESULTS**

**Gradient purification of virions.** Virions were purified from noninfectious enveloped particles, dense bodies, and cellular debris by ultracentrifugation through glycerol-tartrate positive-density, negative-viscosity gradients, as described previously (62, 63). The gradients were centrifuged at 90,465.7 × g for 45 min at 20°C. Virions were recovered by piercing the tubes using a 20-gauge needle and syringe, diluted in 0.04 M sodium phosphate buffer (pH 7.4), and pelleted by centrifugation at 90,465.7 × g for 1 h at 20°C. The virion pellet was resuspended in a medium suitable for downstream applications (see below).

**Western blot analysis.** Purified virions were resuspended in Nu-Page LDS sample buffer, and proteins were separated by using a Nu-page Tris-acetate gel system (Invitrogen) according to the manufacturer’s instructions. Electrophoresed proteins were subsequently transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes (GE Healthcare) by semidy transfer at 10 V for 1 h using carbonate transfer buffer. The membranes were incubated for 1 h at room temperature in blocking buffer (PBS containing 0.1% Tween 20 [PBST] plus 5% [wt/vol] fat-free milk). They were then incubated with primary antibody for 1 h at room temperature, washed three times with PBST, and incubated with secondary antibody for 1 h at room temperature. Antibody was detected by SuperSignal West Pico (Thermo) using an AutoChem imaging system and Labworks software (UVP Bioimaging). Primary antibodies were mouse-anti pUL128 antibody SURN, provided by Giueseppe Gerna (1:100), and mouse anti-gB (1:4,000; Abcam). The secondary antibody was goat anti-mouse horseradish peroxidase (HRP; 1:1,000; GE Healthcare).
UL128L mutants can arise within a single passage of wild-type HCMV in fibroblasts (43). To ensure that the experiments were initiated using genetically homogenous virus preparations, HFFF cells were transfected with infectious BAC clones of each virus. The capacity of virus infection to progress by cell-to-cell spread was assessed by direct measurement of plaque sizes formed under a semisolid overlay (Fig. 1A). In this assay, Merlin-UL128L<sup>mut</sup> consistently generated the largest plaques, whereas TB40-BAC4 and FIX plaques were smaller than those of Merlin-UL128L<sup>wt</sup> but were 4- to 2.5-fold larger, respectively, than those of Merlin-UL128L<sup>wt</sup>. TR produced the smallest plaques of all viruses tested. Consistent with previous work (38), Merlin-UL128L<sup>mut</sup> spread through the HFFF monolayer the fastest (Fig. 1B) and produced the greatest amounts of cell-free virus (Fig. 1C), whereas Merlin-UL128L<sup>wt</sup> spread the slowest and produced the lowest cell-free titers (approximately 1,000-fold less than Merlin-UL128L<sup>mut</sup>). Compared to Merlin-UL128L<sup>wt</sup>, TB40-BAC4 and FIX each spread through the HFFF monolayer faster and produced much higher yields (1,000- and 50-fold, respectively) of cell-free virus. Indeed, the amount of cell-free TB40-BAC4 release was similar to that of Merlin-UL128L<sup>mut</sup>. The TR infections spread very slowly at first, but the rate increased from week 5. Like TB40-BAC4 and FIX, TR also produced peak titers of cell-free virus that exceeded those of Merlin-UL128L<sup>wt</sup> by more than 100-fold. Thus, TB40-BAC4 and FIX displayed more efficient cell-to-cell spread in fibroblasts and produced greater yields of cell-free virus than Merlin containing wild-type UL128L. Cell-to-cell spread of TR in fibroblasts was reduced compared to that of Merlin containing wild-type UL128L, yet peak cell-free titers were significantly higher.

**TABLE 1 BAC-cloned and recombinant HCMV strains used in this study**

| Strain                        | Reference | UL128L origin<sup>a</sup> | GenBank accession no. | Designation in text |
|-------------------------------|-----------|---------------------------|-----------------------|---------------------|
| BAC cloned                    |           |                           |                       |                     |
| Merlin<sup>b</sup>            | 38        | Mutated: G>A in UL128 at nt 176260 (R>stop) | GU179001.1            | Merlin-UL128L<sup>mut</sup> |
| Merlin<sup>b</sup>            | 38        | Native                    | GU179001.1            | Merlin-UL128L<sup>wt</sup> |
| TB40-BAC4                    | 48        | Native                    | EF999921.1            | TB40-BAC4           |
| FIX<sup>b</sup>              | 50        | Native                    | AC146907.1            | FIX                  |
| Clinical sample (nonpassaged) |           |                           |                       |                     |
| 3301                         | 40        | Native                    | GG466044.1            | 3301                 |
| Recombinant Merlin containing variant UL128L |           |                           |                       |                     |
| Merlin                       |           |                           |                       |                     |
| Merlin                       | 3301      |                           |                       | Merlin-UL128L<sup>3301</sup> |
| Merlin                       | TR        |                           |                       | Merlin-UL128L<sup>TR</sup> |
| Merlin                       | TB40-BAC4 |                           |                       | Merlin-UL128L<sup>TB40</sup> |
| Merlin                       | FIX       |                           |                       | Merlin-UL128L<sup>FIX</sup> |
| Recombinant Merlin strains containing unique substitutions in UL128L |           |                           |                       |                     |
| Merlin                       |           |                           |                       |                     |
| Merlin                       | TB40-BAC4: G>T in UL128 at nt 176663 (near splice acceptor site) |                       | Merlin-UL128<sup>G>T</sup> |
| Merlin                       | FIX       | A>G in UL130 at nt 177364 (S72P) |                       | Merlin-UL130<sup>A>G</sup> |

<sup>a</sup> Nucleotide positions are relative to the sequence of BAC-cloned HCMV strain Merlin (GU179001).
<sup>b</sup> GenBank accession numbers for parental viruses are NC_006273 (Merlin), GU179289 (VR1814; parental virus of FIX), and KF021605 (TR).

**FIG 1 Growth characteristics of BAC-cloned strains in fibroblasts.** (A) HFFF cells were transfected with BAC DNA for the indicated viruses and then placed under semisolid overlay. Plaque sizes were measured 2 weeks later. Means and standard deviations are shown. (B) HFFF cells were transfected with BAC DNA for the indicated viruses, and infection was allowed to progress until the monolayer was destroyed. At weekly time points posttransfection (p.t.), the level of infection was estimated by FACS analysis of EGFP-expressing cells. (C) Supernatants from the infections shown in panel B were retained at weekly intervals and titrated on HFFFs to provide a measure of cell-free virus release. (Where indicated, samples were compared by 1-way analysis of variance [ANOVA] followed by Dunnett’s posttest to compare each sample to Merlin-UL128L<sup>wt</sup>.*, P < 0.05; **, P < 0.01; ***, P < 0.001).
Characteristics of each strain could be attributed to UL128L, we replaced UL128L in Merlin with that from TB40-BAC4, FIX, or TR, thereby generating the recombinant viruses Merlin-UL128L<sup>TB40</sup>, Merlin-UL128L<sup>FIX</sup>, and Merlin-UL128L<sup>TR</sup>, respectively (Table 1). Compared to Merlin-UL128L<sup>wt</sup>, acquisition of TB40-BAC4 or FIX UL128L was consistently associated with a 2.5- to 3-fold increased plaque size in fibroblasts (Fig. 3A), an increased rate of cell-free spread (Fig. 3B), and approximately 10-fold increased yields of cell-free virus (Fig. 3C). In contrast, TR UL128L did not alter the rate of cell-to-cell spread of strain Merlin and produced titers of cell-free virus that were comparable to those of Merlin-UL128L<sup>wt</sup>, at least until week 6 posttransfection. However, production of cell-free virus by Merlin-UL128L<sup>TR</sup> increased dramatically by week 7. DNA sequencing of UL128L from cell-free virus during the final time point revealed that all viruses retained their original sequence in UL128L, with the exception of Merlin-UL128L<sup>TR</sup>. Merlin-UL128L<sup>TR</sup> harbored a deletion (nt 176742 to 177247) affecting both UL130 and UL128, as well as a G-to-A mutation at nt 177355 that resulted in a premature stop codon in UL130. Thus, the rapid increase in cell-free virus production by Merlin-UL128L<sup>TR</sup> was correlated with mutation of UL128L.

Measurement of the size of plaques formed by these recombinant viruses in RPE-1 cells (Fig. 3D) revealed that expression of TB40-BAC4 and FIX UL128L reduced the epithelial cell-to-cell spread of Merlin, with plaques 2.5 to 7 times smaller, respectively. However, TR UL128L did not affect the growth characteristics of Merlin. Likewise, time course experiments in epithelial cells showed that transfer of FIX UL128L resulted in reduced speed of dissemination, and transfer of FIX and TB40-BAC4, but not TR, UL128L resulted in 10- to 20-fold increased production of cell-free virus (Fig. 3E and F). Thus, compared to Merlin-UL128L<sup>wt</sup>, the ability of TB40-BAC4 and FIX to produce larger plaques in fibroblasts but smaller plaques in epithelial cells, as well as to produce higher titers of cell-free virus in both cell types, appears to be attributable at least in part to genetic differences in UL128L. However, the differential growth characteristics between TR and Merlin-UL128L<sup>wt</sup> appear to be independent of UL128L.

A single-nucleotide difference in a UL128 intron increases cell-free virus production. TB40-BAC4 infection produced significantly higher titers of cell-free virus than Merlin-UL128L<sup>TB40</sup> in both epithelial and fibroblast cells. Since UL128L clearly makes a major contribution to the differential growth characteristics of TB40-BAC4, we hypothesized that UL128L had acquired a mutation during passage that is compatible with growth in fibroblasts yet permits the virus to retain a degree of epithelial cell tropism. If this were the case, any such mutation would be expected to be unique to TB40-BAC4. UL128L sequences from different strains exhibit a high level of sequence conservation (>92.3% at the nucleotide level [64, 65]); however, BLAST searches revealed that TB40-BAC4 had a unique G-to-T (G>T) substitution at nt 176612 (with reference to the equivalent location in the Merlin BAC genome). The G residue is conserved in 50 other HCMV strains and is located in the first of the two UL128 introns, 6 nt from the splice acceptor site. To determine whether this substitution affects the growth properties of TB40-BAC4, it was introduced into Merlin-UL128L<sup>wt</sup> to generate Merlin-UL128L<sup>G>T</sup> (Table 1). As an additional control, UL128L from strain 3301 was inserted into Merlin (generating Merlin-UL128L<sup>3301</sup>). Strain 3301 had not been subjected to in vitro passage prior to sequencing and

**FIG 2** Growth characteristics of BAC-cloned strains in epithelial cells. (A) RPE-1 cells were transfected with BAC DNA for the indicated viruses and then placed under semisolid overlay. Plaque sizes were measured 3 weeks later. Means and standard deviations are shown. (B) RPE-1 cells were transfected with BAC DNA for the indicated viruses, and infection was allowed to progress until the monolayer was destroyed. At weekly time points, cells were trypsinized and the level of infection was measured by FACS analysis of EGFP-expressing cells. (C) Supernatants from the infections shown in panel B were placed under semisolid overlay. Plaque sizes were measured 3 weeks later.**

Growth properties of HCMV strains FIX, Merlin, TB40-BAC4, and TR in epithelial cells. In order to investigate the growth characteristics of FIX, Merlin, TB40-BAC4, and TR in an epithelial cell line (which requires UL128L for efficient infection), RPE-1 cells were transfected with the infectious BAC clones. In marked contrast to the findings for fibroblasts, Merlin-UL128L<sup>wt</sup> displayed much more efficient plaque formation than Merlin-UL128L<sup>mut</sup> (Fig. 2A). TB40-BAC4 and TR plaques were of an intermediate size (approximately 6 times smaller than Merlin-UL128L<sup>wt</sup>), while FIX formed plaques that were 25 times smaller, similar to those produced by Merlin-UL128L<sup>mut</sup>, TB40-BAC4 and TR each spread throughout the RPE-1 monolayer much more slowly than Merlin-UL128L<sup>wt</sup> (Fig. 2B and C) yet produced 100- to 150-fold higher titers of cell-free virus. Neither FIX nor Merlin-UL128L<sup>mut</sup> supported significant spread through RPE-1 monolayers.

Thus, the growth phenotypes displayed by TB40-BAC4, FIX, and TR in fibroblasts and epithelial cells were distinct from those of Merlin containing wild-type UL128L. Cell-to-cell spread of TB40-BAC4 and FIX was more efficient in fibroblasts but less efficient (along with TR) in epithelial cells. TB40-BAC4, TR, and FIX all produced significantly higher cell-free titers than Merlin-UL128L<sup>wt</sup> in both cell types.

The differential growth characteristics of TB40-BAC4 and FIX are determined by UL128L. To assess whether the growth characteristics of each strain could be attributed to UL128L, we replaced UL128L in Merlin with that from TB40-BAC4, FIX, or TR, thereby generating the recombinant viruses Merlin-UL128L<sup>TB40</sup>, Merlin-UL128L<sup>FIX</sup>, and Merlin-UL128L<sup>TR</sup>, respectively (Table 1). Compared to Merlin-UL128L<sup>wt</sup>, acquisition of TB40-BAC4 or FIX UL128L was consistently associated with a 2.5- to 3-fold increased plaque size in fibroblasts (Fig. 3A), an increased rate of cell-free spread (Fig. 3B), and approximately 10-fold increased yields of cell-free virus (Fig. 3C). In contrast, TR UL128L did not alter the rate of cell-to-cell spread of strain Merlin and produced titers of cell-free virus that were comparable to those of Merlin-UL128L<sup>wt</sup>, at least until week 6 posttransfection. However, production of cell-free virus by Merlin-UL128L<sup>TR</sup> increased dramatically by week 7. DNA sequencing of UL128L from cell-free virus during the final time point revealed that all viruses retained their original sequence in UL128L, with the exception of Merlin-UL128L<sup>TR</sup>. Merlin-UL128L<sup>TR</sup> harbored a deletion (nt 176742 to 177247) affecting both UL130 and UL128, as well as a G-to-A mutation at nt 177355 that resulted in a premature stop codon in UL130. Thus, the rapid increase in cell-free virus production by Merlin-UL128L<sup>TR</sup> was correlated with mutation of UL128L.

Measurement of the size of plaques formed by these recombinant viruses in RPE-1 cells (Fig. 3D) revealed that expression of TB40-BAC4 and FIX UL128L reduced the epithelial cell-to-cell spread of Merlin, with plaques 2.5 to 7 times smaller, respectively. However, TR UL128L did not affect the growth characteristics of Merlin. Likewise, time course experiments in epithelial cells showed that transfer of FIX UL128L resulted in reduced speed of dissemination, and transfer of FIX and TB40-BAC4, but not TR, UL128L resulted in 10- to 20-fold increased production of cell-free virus (Fig. 3E and F). Thus, compared to Merlin-UL128L<sup>wt</sup>, the ability of TB40-BAC4 and FIX to produce larger plaques in fibroblasts but smaller plaques in epithelial cells, as well as to produce higher titers of cell-free virus in both cell types, appears to be attributable at least in part to genetic differences in UL128L. However, the differential growth characteristics between TR and Merlin-UL128L<sup>wt</sup> appear to be independent of UL128L.

A single-nucleotide difference in a UL128 intron increases cell-free virus production. TB40-BAC4 infection produced significantly higher titers of cell-free virus than Merlin-UL128L<sup>TB40</sup> in both epithelial and fibroblast cells. Since UL128L clearly makes a major contribution to the differential growth characteristics of TB40-BAC4, we hypothesized that UL128L had acquired a mutation during passage that is compatible with growth in fibroblasts yet permits the virus to retain a degree of epithelial cell tropism. If this were the case, any such mutation would be expected to be unique to TB40-BAC4. UL128L sequences from different strains exhibit a high level of sequence conservation (>92.3% at the nucleotide level [64, 65]); however, BLAST searches revealed that TB40-BAC4 had a unique G-to-T (G>T) substitution at nt 176612 (with reference to the equivalent location in the Merlin BAC genome). The G residue is conserved in 50 other HCMV strains and is located in the first of the two UL128 introns, 6 nt from the splice acceptor site. To determine whether this substitution affects the growth properties of TB40-BAC4, it was introduced into Merlin-UL128L<sup>wt</sup> to generate Merlin-UL128L<sup>G>T</sup> (Table 1). As an additional control, UL128L from strain 3301 was inserted into Merlin (generating Merlin-UL128L<sup>3301</sup>). Strain 3301 had not been subjected to in vitro passage prior to sequencing and
was thus representative of a UL128L sequence that was different from that of Merlin but that was known to be wild type. UL128L from 3301 was also highly homologous to UL128L from TB40-BAC4 (99.49% at the nucleotide level); however, it did not contain the G>T nucleotide difference identified in the intron of UL128.

Therefore, it was useful to determine whether the G>T substitution, as opposed to natural strain variation elsewhere, contributed to the different characteristics of UL128L from TB40-BAC4 compared to that from Merlin.

Merlin-UL128L\textsuperscript{wt} and Merlin-UL128L\textsuperscript{3301} displayed similar cell-cell spread properties in RPE-1 cells. Transfer of the substitution identified in TB40-BAC4 UL128 was sufficient to reduce epithelial cell-to-cell spread of Merlin to the same degree (approximately 2-fold) as transfer of the entire TB40-BAC4 UL128L (Fig. 4A). Investigations of infection kinetics (Fig. 4B) and production of cell-free virus in epithelial cell culture (Fig. 4C) also showed that Merlin-UL128L\textsuperscript{3301} had growth characteristics similar to those of Merlin-UL128L\textsuperscript{wt}. Transfer of the G>T substitution to Merlin did not alter the rate of spread through the monolayer, but it did increase the production of cell-free virus by Merlin by the same degree as transfer of the entire TB40-BAC4 UL128L (approximately 50-fold). When plaque sizes were measured in fibroblasts (Fig. 4D), Merlin-UL128L\textsuperscript{3301} again formed plaques of sizes comparable to those of Merlin-UL128L\textsuperscript{wt}, whereas the plaques formed by Merlin-UL128\textsuperscript{G>T} were similar in size to those formed by Merlin-UL128LT\textsuperscript{B40} and were consistently 2-fold larger than those formed by Merlin-UL128L\textsuperscript{wt} and Merlin-UL128L\textsuperscript{3301}.

A single-nucleotide difference in a TB40 UL128 intron reduces splicing efficiency. The proximity of the G>T substitution in TB40-BAC4 UL128 to the splice acceptor site in intron 1 suggested that it had the potential to disrupt splicing of UL128 mRNA. Indeed, bioinformatics analysis predicted that this would be the case (Fig. 5A). Total infected cell RNA was extracted 72 h postinfection, and RT-PCR was performed across both introns of UL128 (Fig. 5B). Three differently spliced products were detected, and DNA sequencing demonstrated that they corresponded to (i) an unspliced transcript (656 to 662 bp, depending on the strain), (ii) a transcript with intron 2 excised (540 bp), and (iii) a transcript with both introns 1 and 2 excised (417 bp). All three UL128 products were detected in all strains tested; however, in the constructs containing the G>T substitution (TB40-BAC4, Merlin-UL128L\textsuperscript{B40}, and Merlin-UL128\textsuperscript{G>T}), the cDNAs corresponding to the fully spliced transcript were present at significantly lower abundance.

Thus, the G>T substitution identified in TB40-BAC4 reduced the efficiency of UL128 mRNA splicing and appeared to be entirely responsible for the different growth characteristics conferred by TB40-BAC4 UL128L compared to those of Merlin-UL128L.

A single-nucleotide difference in FIX UL130 increases virus production. BLAST searches of UL128L sequences also revealed a unique A-to-G (A>G) substitution in FIX UL130 at nt 177364 (with reference to the Merlin BAC sequence). This difference manifests as a serine-to-proline amino acid change (S72P), and according to protein structure prediction, it disrupts a beta sheet manifesting as a serine-to-proline amino acid change (S72P), and according to protein structure prediction, it disrupts a beta sheet within the protein. The alteration was introduced into Merlin-UL128L\textsuperscript{wt} (generating Merlin-UL130\textsuperscript{A>G}) (Table 1). Merlin-UL130\textsuperscript{A>G} produced plaques in RPE-1 cells approximately 3-fold smaller than those of Merlin-UL128L\textsuperscript{wt} but similar in size to those formed by Merlin-UL128LT\textsuperscript{B40} (Fig. 6A). The effects of this substitution on dissemination during infection (Fig. 6B) and cell-free virus production (Fig. 6C) in epithelial cell culture were also investigated. It reduced the rate of dissemination through the epithelial cell monolayer compared to that of Merlin-UL128L\textsuperscript{wt}, although not as much as transfer of the entire FIX UL128L. It also
increased the production of cell-free virus approximately 50-fold compared to that of Merlin-UL128L<sup>wt</sup>. As with the rate of spread through the monolayer, the increase in cell-free release was not as dramatic as that achieved by transfer of the entire FIX UL128L (approximately 150-fold). When cell-to-cell spread ability was tested in HFFFs (Fig. 6D), Merlin-UL130<sup>A/H11022</sup>G and Merlin-UL128L<sup>FIX</sup> formed plaques of comparable size, and the plaques were consistently twice as large as those formed by Merlin-UL128L<sup>wt</sup>.

Thus, the A>G substitution in FIX UL130 contributed significantly to the different growth characteristics of FIX UL128L compared to those of Merlin UL128L.

**pUL128 is reduced in TB40-BAC4 and FIX virions.** The substitutions in TB40-BAC4 and FIX UL128L identified above have the potential to influence the function of gH/gL/UL128L by various mechanisms. Impairing the efficiency of RNA splicing in TB40-BAC4 would be expected to limit expression of full-length pUL128, and the S72P substitution in pUL130 might reduce the stable incorporation of pUL130 into gH/gL/UL128L or affect a functional domain of the complex. Since all five subunits are required for stable incorporation of gH/gL/UL128L into the virion (<sup>28</sup>, <sup>66</sup>), alteration of the amounts or structural attributes of any one component has the potential to affect the levels of the entire complex incorporated into the virion. To investigate this, levels of pUL128 were analyzed in HCMV virions purified on glycerol-tartrate gradients (Fig. 7A), with sample loading normalized to that of gB. Note that although the epitope recognized by the anti-UL128 antibody used in this assay is not mapped, any differences in detection are unlikely to be due to different antibody affinities for pUL128 from different strains; compared to Merlin, UL128 in the other strains differed by only one (FIX) or two (TB40-BAC4 and TR) amino acids, while in Merlin viruses containing the single-nucleotide substitutions from FIX or TB40-BAC4, pUL128 is identical to Merlin.
However, TB40-BAC4 contained reduced levels of pUL128, as did Merlin containing either the entire TB40-BAC4 UL128L region (Merlin-UL128L wt) or only the G/H11022 T substitution (Merlin-UL128L G/H11022 T). pUL128 was undetectable in FIX and Merlin-UL128L FIX, while Merlin-UL130 A/H11022 G contained reduced, though detectable, levels of pUL128.

Based on the spread of these viruses in epithelial cells, it seemed likely that all except Merlin-UL128L mut contained gH/gL/UL128L in the virion, and that lack of detection of pUL128 in some was due to the small amounts of virus loaded in order to keep sample loading comparable to that of the low-titer viruses Merlin-UL128L wt and Merlin-UL128L 3301. In a separate blot where the virion load was not normalized, pUL128L was detectable in all virions except Merlin-UL128L mut (Fig. 7B).

Thus, all virions except Merlin-UL128L mut contain pUL128; however, the substitutions identified in UL128L of TB40-BAC4 and FIX resulted in reduced levels of gH/gL/UL128L being incorporated into the virion.

TB40-BAC4 and FIX UL128L bestow impaired epithelial cell tropism. Since gH/gL/UL128L is required for efficient infection of epithelial cells, its reduced incorporation into virions would be expected to restrict epithelial cell tropism. Viruses derived from each BAC-cloned strain were plaque titrated on HFFF and RPE-1 cells in parallel (Fig. 8A). For each virus, the titer reported in RPE-1 cells was normalized to that reported for HFFF cells for the same virus, thereby quantitating the ability of each virus to infect epithelial cells relative to its ability to infect fibroblasts. Merlin-UL128L mut infected RPE-1 cells approximately 100-fold less efficiently than HFFFs; however, the majority of plaques were represented by single cells, indicating that cell-to-cell spread was strongly inhibited. Viruses containing wild-type UL128L (Merlin-UL128L wt and Merlin-UL128L 3301) infected RPE-1 cells with comparable or slightly greater efficiency than they did HFFFs. Like Merlin-UL128L wt and Merlin-UL128L 3301, TR infected RPE-1 and HFFF cells with similar efficiencies, consistent with these viruses containing comparable levels of gH/gL/UL128L in virions. However, infection of RPE-1 cells by TB40-BAC4 was approxi-
infected RPE-1 cells approximately 10-fold less efficiently than HFFFs (Fig. 8B), displaying a lower infection efficiency than Merlin-UL128L \textsuperscript{wt}, Merlin-UL128L \textsuperscript{mm} and TR.

FIX infected epithelial cells with approximately 100-fold less efficiency than fibroblasts, and this was closely recapitulated by Merlin containing FIX UL128L (Fig. 8C). The A\textgreater G substitution in FIX UL130 also reduced the ability of Merlin to infect RPE-1 cells, although only by approximately 10-fold.

In summary, the unique nucleotide differences identified in TB40-BAC4 UL128L and FIX UL130 resulted in a reduction in the amounts of gH/gL/UL128L incorporated into the virion and a concomitant reduction in the relative ability of virus to infect epithelial cells.

**DISCUSSION**

Previous attempts to propagate wild-type HCMV from clinical material by passage in vitro in fibroblasts have shown that mutations invariably occur in the viral genome. RL13 mutates first, followed by UL128L, and following these steps virus grows to much higher cell-free titers (37, 38). However, the adapted virus lacks gH/gL/UL128L in the virion envelope; therefore, it does not efficiently infect cells other than fibroblasts. The single-nucleotide substitutions identified in UL128L of TB40-BAC4 and FIX may explain the apparently conflicting fact that these strains retain the ability to infect endothelial and epithelial cells when passaged on fibroblasts. gH/gL/UL128L is expressed and is present in virions of these strains, but the level is reduced. This permits greater release of cell-free virus and potentially reduces the selective pressure for further mutations in UL128L.

It is important to determine whether these substitutions represent natural strain variation or mutations acquired in vitro. The clinical material from which the strains were derived is not available; therefore, it is not possible to answer this question directly. However, the S72P substitution in FIX UL130 is absent from the passaged parental strain VR1814 (37); thus, it probably occurred during further passage of VR1814 prior to BAC cloning. Similarly, the fact that the G\textgreater T substitution in intron 1 of TB40-BAC4 is unique to TB40-BAC4 strongly suggests that it was acquired during passage in fibroblasts prior to BAC cloning. This mutation is also absent from the consensus sequence of the parental strain (TB40/E), which instead contains a unique C207S variation in UL130. TB40/E is known to comprise a mixture of genomes (48), and the G\textgreater T mutation may be present at low levels in this mixture. Nevertheless, the identification of the substitutions in FIX and TB40-BAC4 demonstrates the importance of comparing viral genomes to unpassaged virus when determining whether a gene is wild type in sequence and whether (by extension) the phenotype of a virus can be assumed to be the same as the clinical virus.

The effect of these substitutions was a reduction in levels of gH/gL/UL128L in the virion. This manifested in impaired efficiency of epithelial cell entry, an increase in cell-to-cell spread in fibroblasts but a decrease in cell-to-cell spread in epithelial cells, and an increase in cell-free release in both cell types. Taken together, these observations indicate that the level of gH/gL/UL128L in the virion is directly related to its ability to inhibit replication in fibroblasts and to promote entry and cell-to-cell spread in epithelial cells. Surprisingly, it also suggests that wild-type UL128L inhibits the production of cell-free virus in both epithelial and fibroblast cells. The mechanism by which this occurs is unclear but may be related to the fact that gH and gL are common to two glycopro-
tein complexes (gH/gL/UL128L and gH/gL/gO). Greater amounts of gH/gL/UL128L may result in there being less gH/gL available for the formation of gH/gL/gO. gH/gL/gO may be important for secondary envelopment of progeny virions and egress into the supernatant (23) and for subsequent infection by cell-free released virus (24, 67), explaining the increased titers of cell-free virus as the level of gH/gL/UL128L is reduced. This model is supported by the observation that expression of wild-type UL128L reduces levels of both cell-free and cell-associated virus (37), and that loss of gO results in greater accumulation of gH/gL/UL128L in the virion with a concomitant increase in cell-to-cell spread in epithelial and endothelial cells (24).

Although the mutations identified in FIX and TB40-BAC4 strongly contributed to the greater production of cell-free virus and differences in cell-to-cell spread, it is clear that they are not the sole reason for the growth differences seen in TB40-BAC4 and FIX compared to Merlin-UL128L\textsuperscript{wt}. TB40-BAC4 grew to approximately 1,000-fold higher cell-free titers than Merlin-UL128L\textsuperscript{wt}, whereas transfer of the G\textsuperscript{243}T mutation in TB40-BAC4 UL128 resulted in an increase of only 50-fold. Likewise, FIX was unable to spread cell to cell in RPE-1 epithelial cells, yet Merlin-UL128L\textsuperscript{FIX} was able to spread, albeit more slowly than Merlin-UL130\textsuperscript{G243S-G}, which itself spread more slowly than Merlin-UL128L\textsuperscript{wt}. Similar considerations apply to TR. Despite containing levels of gH/gL/UL128L similar to those in Merlin-UL128L\textsuperscript{wt}, TR generated higher cell-free titers yet displayed lower efficiency of cell-to-cell spread in both fibroblast and epithelial cells. The observation that Merlin-UL128L\textsuperscript{TR} behaved the same as Merlin-UL128L\textsuperscript{wt} and Merlin-UL128L\textsuperscript{301}, and that TR UL128L readily mutated when expressed in the Merlin genome during growth in fibroblasts but not when expressed within the TR genome, underlines the conclusion that the differential growth characteristics of TR were independent of UL128L yet are sufficient to enhance the stability of UL128L in vitro. These differences may be due to a number of other genome regions that can influence growth in a cell type-specific manner (37, 68–70). Sequence differences in other glycoproteins might also be responsible, with gO being a particularly prominent candidate because it exists in several highly divergent, yet stable, genotypes (43, 71–73). Alignments of the protein-coding regions of gH, gL, gM, gN, gO, and gB of TR, TB40-BAC4, and FIX with those of other strains did not reveal any unique substitutions that could represent in vitro adaptations, although all 3 viruses lack sequences in Us, where the BAC cassette was inserted, and TB40-BAC4 contains mutations in RLS5A, RL6, UL141, and UL40 (48, 74), and TR contains a mutation in UL97 (C607Y) that conveys ganciclovir resistance (75). These mutations could also contribute to the growth characteristics observed.

Owing to its central role in determining tropism for a broad range of clinically significant cell types, it is essential that an intact, wild-type gH/gL/UL128L is present in any strain used to investigate HCMV pathogenesis. More recently, other important implications of UL128L function have underscored the need for research based on virus strains that are competent in this genome region. Specifically, gH/gL/UL128L elicits a potent neutralizing antibody response in a natural infection (76–81) and is considered ideal for inclusion in new vaccine strategies (34, 82). The differences identified between levels of gH/gL/UL128L in various strains analyzed have the potential to affect read-outs of the efficacy of anti-gH/gL/UL128L antibodies. However, they also offer significant advantages relating to the important issue of being able to grow HCMV while minimizing the risk of mutation. For work performed in fibroblast cells, viruses based on Merlin-UL128L\textsuperscript{mut} offer an ideal defined, full-length genome that produces relatively high titers. For work requiring infection of other cell types, Merlin-UL128L\textsuperscript{G243-T} produces larger amounts of cell-free virus that is still able to infect epithelial and endothelial cells, potentially with reduced risk of mutation in UL128L.

ACKNOWLEDGMENTS

This work was funded by the National Institute for Social Care and Health (NISCHR), the Medical Research Council (MRC), and the Wellcome Trust.

We thank Gavin Wilkinson for critical reading of the manuscript.

REFERENCES

1. Mocarski ES. 2007. Cytomegalovirus, p 2447–2492. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.

2. Adler B, Sinzger C. 2009. Endothelial cells in human cytomegalovirus infection: one host cell out of many or a crucial target for virus spread? Thromb. Haemost. 102:1057–1063.

3. Sinclair J, Sissons P. 2006. Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87:1763–1779.

4. Compton T, Nowlin DM, Cooper NR. 1993. Initiation of human cytomegalovirus infection requires initial interaction with cell surface heparan sulfate. Virology 193:834–841.

5. Boyle KA, Compton T. 1998. Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B. J. Virol. 72:1826–1833.

6. Britt WJ, Boppana S. 2004. Human cytomegalovirus virion proteins. Hum. Immunol. 65:395–402.

7. Kari B, Gehrz R. 1992. A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope. J. Virol. 66:1761–1764.

8. Feire AL, Koss H, Compton T. 2004. Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain. Proc. Natl. Acad. Sci. U. S. A. 101:15470–15475.

9. Wang X, Huong SM, Chiu ML, Raab-Traub N, Huang ES. 2003. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424:456–461.

10. Sorocceanu I, Akhavan A, Cobbs CS. 2008. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 453:391–395.

11. Chan G, Nogalski MT, Yurochko AD. 2009. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc. Natl. Acad. Sci. U. S. A. 106:22349–22354.

12. Issacson MK, Feire AL, Compton T. 2007. Epidermal growth factor receptor is not required for human cytomegalovirus entry or signaling. J. Virol. 81:6241–6247.

13. Vanarsdall AL, Wriser TW, Lei H, Kazlauskas A, Johnson DC. 2012. PDGF receptor-alpha does not promote HCMV entry into epithelial and endothelial cells but increased quantities stimulate entry by an abnormal pathway. PLoS Pathog. 8:e1002905. doi:10.1371/journal.ppat.1002905.

14. Kinzler ER, Compton T. 2005. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J. Virol. 79:7827–7837.

15. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, Heldwein EE. 2010. Crystal structure of the conserved herpesvirus fusion regulator complex gH–gL. Nat. Struct. Mol. Biol. 17:882–888.

16. Issacson MK, Compton T. 2009. Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J. Virol. 83:3891–3903.

17. Lopper M, Compton T. 2004. Coiled-coil domains in glycoproteins B and H are involved in human cytomegalovirus membrane fusion. J. Virol. 78:8333–8341.

18. Vanarsdall AL, Ryckman BJ, Chase MC, Johnson DC. 2008. Human cytomegalovirus glycoproteins gB and gHgL mediate epithelial cell-cell fusion when expressed either in cis or in trans. J. Virol. 82:11837–11850.

19. Compton T, Nepomuceno RR, Nowlin DM. 1992. Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface. Virology 191:387–395.

20. Haspot F, Lavault A, Sinzger C, Laib Sampaio K, Stierhof YD, Pilet P, Lopper M, Compton T. 2013. Crystal structure of the conserved herpesvirus fusion regulator complex gH–gL. Nat. Struct. Mol. Biol. 17:882–888.
21. Sinzger C. 2008. Entry route of HCMV into endothelial cells. J. Clin. Virol. 41:174–179.
22. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. 2006. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol. 80:710–722.
23. Jiang XJ, Adler B, Sampaio KL, Digel M, Jahn G, Ettischer N, Stierhof Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. 2006. UL74 of human cytomegalovirus contributes to virus release by promoting secondary envelopment of virions. J. Virol. 82:2802–2812.
24. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC. 2009. An HCMV gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts, epithelial, and endothelial cells. J. Virol. 83:2585–2596.
25. Adler B, Scrivano L, Ruizcics Z, Rupp B, Sinzger C, Koszinowski U. 2005. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev. Med. Virol. 11:191–200.
26. Wang D, Shenk T. 2002. The human cytomegalovirus ribonucleotide reductase homolog UL45 is dispensable for growth in endothelial cells and virus transfer to leukocytes. J. Virol. 76:10023–10033.
27. Ryckman BJ, Chase MC, Johnson DC. 2008. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell type-specific receptors. Proc. Natl. Acad. Sci. U. S. A. 105:14118–14123.
28. Ryckman BJ, Rainish BL, Chase MC, Borton JA, Nelson JA, Jarvis MA, Johnson DC. 2008. Characterization of the human cytomegalovirus gH/gL/UL128-131 complex that mediates entry into epithelial and endothelial cells. J. Virol. 82:60–70.
29. Schuessler A, Sampaio KL, Scrivano L, Sinzger C. 2010. Mutational mapping of UL130 of human cytomegalovirus defines peptide motifs within the C-terminal third as essential for endothelial cell infection. J. Virol. 84:9019–9026.
30. Schuessler A, Sampaio KL, Sinzger C. 2010. Charge cluster-to-alanine scanning of UL128 for fine tuning of the endothelial cell tropism of human cytomegalovirus. J. Virol. 82:11239–11246.
31. Schuessler A, Sampaio KL, Straschewski S, Sinzger C. 2012. Mutational mapping of UL131A of human cytomegalovirus emphasizes its central role for endothelial cell tropism. J. Virol. 86:2460–2466.
32. Straschewski S, Patrone M, Walther P, Gallina A, Mertens T, Frascaroli G. 2011. Protein pUL128 of human cytomegalovirus is necessary for monocytie infection and blocking of migration. J. Virol. 85:5150–5158.
33. Wang D, Shenk T. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J. Virol. 79:10330–10338.
34. Revello MG, Gerna G. 2010. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev. Med. Virol. 20:136–155.
35. Gerna G, Percivalle E, Lilleri D, Lozza I, Fornara C, Hahn G, Baldanti F, Revello MG. 2005. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131A-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J. Gen. Virol. 86:275–284.
36. Sinzger C, Kahl M, Laib K, Kriegl K, Rieger P, Plachter B, Jahn G. 2002. Tropism of human cytomegalovirus for endothelial cells is determined by a post-entry step dependent on efficient translocation to the nucleus. J. Gen. Virol. 83:3021–3035.
37. Dargan DJ, Douglass E, Cunningham C, Jamieson F, Stanton RJ, Baluchova K, McSharry BP, Tomasec P, Emmery VC, Percivalle E, Saraisan A, Gerna G, Wilkinson GW, Davison AJ. 2010. Sequence variation in the complete human cytomegalovirus genome in a BAC reveals R1L3 to be a potent inhibitor of replication. J. Clin. Investig. 120:3191–3208.
38. Akister P, Cunningham C, McSharry BP, Dolan A, Addison C, Dargan DJ, Hassan-Walker AF, Emmery VC, Griffiths PD, Wilkinson GW, Davison AJ. 2003. Two novel spliced genes in human cytomegalovirus. J. Gen. Virol. 84:1117–1122.
39. Cunningham C, Gatherer D, Hilfrich B, Baluchova K, Dargan DJ, Thomson M, Griffiths PD, Wilkinson GW, Schulz TF, Davison AJ. 2010. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J. Gen. Virol. 91:605–615.
40. Sinzger C, Schmidt K, Knapp J, Kahl M, Beck R, Waldman J, Hebart H, Einsele H, Jahn G. 1999. Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J. Gen. Virol. 80:2867–2877.
41. Cha T, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70:78–83.
42. Dolan A, Cunningham C, Hector RD, Hassan-Walker AF, Lee L, Addison C, Dargan DJ, McGeoch DJ, Gatherer D, Emery VC, Griffiths PD, Sinzger C, McSharry BP, Wilkinson GW, Davison AJ. 2004. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol. 85:1301–1312.
43. Prichard M, Penfold M, Duke G, Spaete R, Kemble G. 2001. Re-engineering adenovirus vector systems to enable high-throughput Western blot analysis of cellular protein expression. J. Virol. 75:8607–8612.
44. Matrosovich M, Matrosovich T, Garten W, Klenk HD. 2006. New low-virus overlay medium for viral plaque assays. Virol. J. 3:63.
45. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. 2005. Simple and highly efficient BAC recombineering using galk selection. Nucleic Acids Res. 33:36. doi: 10.1093/nar/gni035.
46. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. 2008. Re-engineering adeno-virus vector systems to enable high-throughput analyses of gene function. Biotechniques 45:569–564.
47. Reese MG, Deckman FH, Kulp D, Haussler D. 1997. Improved splice site detection in Genie. J. Comput. Biol. 4:311–323.
48. Brunak S, Engelbrecht J, Knudsen S. 1991. Prediction of human mRNA donor and acceptor sites from the DNA sequence. J. Mol. Biol. 220:49–65.
49. Dogan RI, Getoor L, Wilbur WJ, Mount SM. 2007. SplicePort—an interactive splice-site analysis tool. Nucleic Acids Res. 35:W283–W291.
50. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M,
